zoledronic acid has been researched along with etidronate in 79 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (1.27) | 18.2507 |
| 2000's | 38 (48.10) | 29.6817 |
| 2010's | 36 (45.57) | 24.3611 |
| 2020's | 4 (5.06) | 2.80 |
| Authors | Studies |
|---|---|
| Martin, MB; Oldfield, E; Szabo, CM | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Almeida Paz, FA; Barbosa, JS; Braga, SS | 1 |
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Agabian, N; Byington, CL; Cohen, FE; Dunbrack, RL; Whitby, FG | 1 |
| Berenson, J; Hortobagyi, G; Lipton, A; Major, PP | 1 |
| Getz, B; Ingle, JN; Pederson, L; Reinholz, GG; Sanders, ES; Spelsberg, TC; Subramaniam, M | 1 |
| Lortholary, A | 1 |
| Getz, B; Ingle, JN; Karpeisky, MY; Mikhailov, SN; Padyukova, NSh; Reinholz, GG; Sanders, ES; Spelsberg, TC | 1 |
| Boissier, S; Cabon, F; Clézardin, P; Colombel, M; Filleur, S; Fournier, P; Guglielmi, J | 1 |
| Berenson, JR | 1 |
| Reid, IR | 2 |
| Hershman, D; Narayanan, R | 1 |
| Khuri, F; Saba, N | 1 |
| Chapurlat, RD | 1 |
| Brown, JP; Fraser, W; Hosking, D; Luchi, M; Lyles, K; Mesenbrink, P; Miller, P; Pak, J; Reid, IR; Richardson, P; Saidi, Y; Su, G; Zelenakas, K | 1 |
| Liel, Y | 1 |
| De Filippo, G; Mossetti, G; Rendina, D | 1 |
| Füessl, HS | 1 |
| Hosking, D | 1 |
| Franke, HR; Verdijk, R; Vermes, I; Wolbers, F | 1 |
| Aldrich, W; Harris, KW; Merrell, MA; Millender-Swain, T; Selander, KS; Triozzi, P; Wakchoure, S | 1 |
| Dunford, JE; Ebetino, FH; Guo, K; Kavanagh, KL; Knapp, S; Oppermann, U; Rogers, MJ; Russell, RG; Wu, X | 1 |
| Krane, SM | 1 |
| Brown, JP; Curiel, MD; Devogelaer, JP; Eriksen, EF; Fashola, T; Fraser, WD; Hooper, M; Hosking, D; Lyles, K; Miller, P; Pak, J; Reid, IR; Saidi, Y; Su, G; Zelenakas, K | 1 |
| Adachi, JD; Beattie, K; Bobba, RS; Kumbhare, D; Parkinson, B | 1 |
| Botsis, D; Christodoulakos, G; Lambrinoudaki, I | 1 |
| Camm, J; Karam, R; McClung, M | 1 |
| Mukherjee, S; Oldfield, E; Song, Y | 1 |
| Abelson, A | 1 |
| Márton, I; Redl, P; Udvardy, E | 1 |
| Barnett, BL; Deprèle, S; Ebetino, FH; Evdokimov, A; Hogan, JM; Kashemirov, BA; McKenna, CE | 1 |
| Martens, MG; Shaw, H | 1 |
| Hochberg, MC | 1 |
| Okazaki, R | 1 |
| Matsumoto, T | 1 |
| Bilezikian, JP | 1 |
| Bilezikian, JP; Gennari, L | 1 |
| Devogelaer, JP; Fashola, T; Ferreira, A; Hartl, F; Lau, CS; Mesenbrink, P; Papanastasiou, P; Reginster, JY; Reid, DM; Roux, C; Saag, K; Sambrook, PN | 1 |
| Allen, MR; Burr, DB; Feher, A; Fuchs, RK; Koivunemi, A; Koivunemi, M; Phipps, RJ; Reinwald, S | 1 |
| Baziotis, N; Limouris, GS; Zafeirakis, A; Zissimopoulos, A | 1 |
| Barnett, BL; Dunford, JE; Ebetino, FH; Lawson, MA; Locklin, RM; Phipps, RJ; Russell, RG; Triffitt, JT; Xia, Z | 1 |
| Bolland, MJ; Gamble, GD; Grey, AB; Reid, IR | 1 |
| Endo, Y; Funayama, H; Kawamura, H; Kumamoto, H; Kuroishi, T; Oizumi, T; Sasaki, K; Sugawara, S; Takahashi, H; Yamaguchi, K; Yamamoto, M; Yokoyama, M | 1 |
| Henry, C; Jahnke, W | 1 |
| Maricic, M | 1 |
| Bellahcène, A; Benzaïd, I; Castronovo, V; Clézardin, P; Colombel, M; Ebetino, FH; Fournier, PG; Mönkkönen, H; Stresing, V | 1 |
| Choi, SC; Kim, GT; Kim, KC; Kwon, YD | 1 |
| Abrams, J; Bhargaval, A; Graff, JJ; Nahleh, Z; Nirmal, K | 1 |
| Pazianas, M | 1 |
| Bhattacharyya, I; Bowers, LM; Cohen, DM; Fitzpatrick, SG; Green, JG; Hinkson, DW; Neuman, AN; Stavropoulos, MF | 1 |
| Bucci-Rechtweg, C; Devogelaer, JP; Lau, CS; Papanastasiou, P; Reginster, JY; Reid, DM; Roux, C; Saag, K; Sambrook, PN; Su, G | 1 |
| Bucci-Rechtweg, C; Devogelaer, JP; Lau, CS; Reginster, JY; Reid, DM; Roux, C; Saag, K; Sambrook, PN; Su, G | 1 |
| de Macedo Dossin, F; Feng, X; Freitas-Junior, LH; Hui, R; Lee, E; Liu, YL; No, JH; Oldfield, E; Wang, K; Yoo, JA; Zhang, Y; Zhu, W | 1 |
| Britton, C; Walsh, J | 1 |
| Clark, OA; Djulbegovic, B; Glasmacher, A; Kumar, A; Mhaskar, R; Miladinovic, B; Redzepovic, J; Wheatley, K | 1 |
| Halpin, C; McKenna, MJ; Merchant, SN; Quesnel, AM; Seton, M | 1 |
| Arranz Caso, JA; Dominguez-Mompello, JL; Flores Ballester, E; López Pizarro, V; Ngo Pombe, S; Restoy Lozano, A | 1 |
| Dohdoh, M; Endo, Y; Kuroishi, T; Nagai, Y; Ohki, A; Oizumi, T; Sugawara, S; Tanaka, Y | 1 |
| Bucci-Rechtweg, C; Collette, J; Devogelaer, JP; Goemaere, S; Ish-Shalom, S; Papanastasiou, P; Reginster, JY; Reid, DM; Sambrook, P; Su, G | 1 |
| Fujimoto, Y; Muramatsu, K; Murayama, M; Nakata, E; Nomura, T; Ogane, S; Sekine, R; Shibahara, T; Shibui, T; Uchiyama, T; Watanabe, A; Yakushiji, T; Yamamoto, N | 1 |
| Gandhi, S; Modi, A; Sen, S; Siris, ES; Tang, J | 1 |
| Endo, Y; Kiyama, T; Kuroishi, T; Oizumi, T; Okada, S; Sasaki, K; Sato, E; Sugawara, S; Takahashi, T; Tanaka, Y | 1 |
| Elahian, F; Lage, H; Mansouri, M; Mirzaei, SA; Mousavi, SS | 1 |
| Chikazu, D; Hamada, H; Koizumi, T; Matsuo, A; Satomi, T | 1 |
| Cai, HF; Li, YT; Zhang, ZL | 1 |
| Auriola, S; Coimbra de Sousa, S; Ebert, R; Graser, S; Hofbauer, LC; Jakob, F; Määttä, J; Meissner-Weigl, J; Mentrup, B; Rachner, TD; Zeck, S | 1 |
| Arponen, H; Haukka, J; Mäkitie, O; Valta, H; Vuorimies, I; Waltimo-Sirén, J | 1 |
| Hwang, SJ; Kim, IS; Lee, B; Lim, SS | 1 |
| Gorai, B; Sivaraman, T | 1 |
| Intorcia, M; Karlsson, L; Mesterton, J; Overbeek, J; Ström, O; Tepie, MF | 1 |
| Djulbegovic, B; Kumar, A; Mhaskar, R; Miladinovic, B | 1 |
| Chowdhury, A; Karamched, SR; Nosoudi, N; Parasaram, V; Parrish, J; Siclari, S | 1 |
| Min, N; Shi, L; Wang, F; Xue, QY | 1 |
| Adams, A; Heidenreich, A; Jakob, T; Kuhr, K; Macherey, S; Monsef, I; Skoetz, N; Tesfamariam, YM | 1 |
| Colarossi, G; Driessen, A; Eschweiler, J; Maffulli, N; Migliorini, F; Oliva, F | 1 |
26 review(s) available for zoledronic acid and etidronate
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Bisphosphonates, Old Friends of Bones and New Trends in Clinics.
Topics: Animals; Bone and Bones; Bone Density Conservation Agents; Bone Diseases; Diphosphonates; Drug Compounding; Drug Delivery Systems; Humans | 2021 |
Oral bisphosphonates: A review of clinical use in patients with bone metastases.
Topics: Alendronate; Biological Availability; Bone Density; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Calcium; Clodronic Acid; Diphosphonates; Double-Blind Method; Etidronic Acid; Humans; Ibandronic Acid; Imidazoles; Male; Multiple Myeloma; Pamidronate; Prostatic Neoplasms; Pyridines; Randomized Controlled Trials as Topic; Risedronic Acid; Zoledronic Acid | 2000 |
[Tumor-induced hypercalcemia. Review of bisphosphonate treatment].
Topics: Diagnosis, Differential; Diagnostic Errors; Diphosphonates; Etidronic Acid; Fluid Therapy; Hematologic Neoplasms; Humans; Hypercalcemia; Imidazoles; Neoplasms; Pamidronate; Prognosis; Recurrence; Sodium Chloride; Treatment Outcome; Zoledronic Acid | 2001 |
Treatment of hypercalcemia of malignancy with bisphosphonates.
Topics: Bone Resorption; Clinical Trials as Topic; Clodronic Acid; Diphosphonates; Etidronic Acid; Humans; Hypercalcemia; Ibandronic Acid; Imidazoles; Neoplasms; Pamidronate; Zoledronic Acid | 2002 |
Bisphosphonates: new indications and methods of administration.
Topics: Alendronate; Animals; Diphosphonates; Etidronic Acid; Fractures, Spontaneous; Humans; Imidazoles; Osteoporosis; Risedronic Acid; Structure-Activity Relationship; Zoledronic Acid | 2003 |
Prevention and management of osteoporosis in women with breast cancer and men with prostate cancer.
Topics: Absorptiometry, Photon; Alendronate; Antineoplastic Agents; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Breast Neoplasms; Calcitonin; Calcium; Clodronic Acid; Diphosphonates; Drug Therapy, Combination; Estrogens; Etidronic Acid; Female; Humans; Imidazoles; Male; Osteoporosis; Prostatic Neoplasms; Quality of Life; Risedronic Acid; Risk Factors; Treatment Outcome; Vitamin D; Zoledronic Acid | 2004 |
The role of bisphosphonates in the management of advanced cancer with a focus on non-small-cell lung cancer. Part 1: Mechanisms of action, role of biomarkers and preclinical applications.
Topics: Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Clodronic Acid; Diphosphonates; Etidronic Acid; False Negative Reactions; Fluorodeoxyglucose F18; Humans; Ibandronic Acid; Imidazoles; Lung Neoplasms; Pamidronate; Positron-Emission Tomography; Predictive Value of Tests; Therapeutic Equivalency; Zoledronic Acid | 2005 |
Pharmacological therapy of Paget's and other metabolic bone diseases.
Topics: Bone Density Conservation Agents; Bone Resorption; Clinical Trials as Topic; Diphosphonates; Etidronic Acid; Humans; Imidazoles; Osteitis Deformans; Osteogenesis; Risedronic Acid; Zoledronic Acid | 2006 |
Tolerability of different dosing regimens of bisphosphonates for the treatment of osteoporosis and malignant bone disease.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Etidronic Acid; Humans; Ibandronic Acid; Imidazoles; Osteonecrosis; Osteoporosis; Risedronic Acid; Zoledronic Acid | 2006 |
Bisphosphonates.
Topics: Alendronate; Diphosphonates; Drug Administration Schedule; Etidronic Acid; Female; Humans; Ibandronic Acid; Imidazoles; Osteoporosis; Osteoporosis, Postmenopausal; Risedronic Acid; Zoledronic Acid | 2006 |
A review of Paget's disease of bone with a focus on the efficacy and safety of zoledronic acid 5 mg.
Topics: Aged; Bone Density Conservation Agents; Diphosphonates; Disease Progression; Etidronic Acid; Humans; Imidazoles; Middle Aged; Osteitis Deformans; Pamidronate; Risedronic Acid; Risk Factors; Treatment Outcome; Zoledronic Acid | 2008 |
[Osteonecrosis of the jaw developing during bisphosphonate treatment].
Topics: Alendronate; Anti-Infective Agents; Bone Density Conservation Agents; Bone Neoplasms; Bone Remodeling; Clodronic Acid; Diphosphonates; Etidronic Acid; Humans; Ibandronic Acid; Imidazoles; Mandible; Mandibular Diseases; Oral Hygiene; Oral Surgical Procedures; Osteonecrosis; Patient Care Team; Referral and Consultation; Zoledronic Acid | 2008 |
Nonvertebral fracture risk reduction with nitrogen-containing bisphosphonates.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Diphosphonates; Dose-Response Relationship, Drug; Etidronic Acid; Female; Fractures, Bone; Humans; Ibandronic Acid; Imidazoles; Male; Osteoporosis; Randomized Controlled Trials as Topic; Risedronic Acid; Risk Factors; Spinal Fractures; Zoledronic Acid | 2008 |
[New development in bisphosphonate treatment. Characteristics and effectiveness of intermittent bisphophonates].
Topics: Alendronate; Bone Density Conservation Agents; Clinical Trials as Topic; Diphosphonates; Drug Administration Schedule; Etidronic Acid; Fractures, Spontaneous; Humans; Ibandronic Acid; Imidazoles; Osteoporosis; Patient Compliance; Risedronic Acid; Zoledronic Acid | 2009 |
Efficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosis.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Fractures, Spontaneous; Humans; Ibandronic Acid; Imidazoles; Osteoporosis, Postmenopausal; Risedronic Acid; Zoledronic Acid | 2009 |
Effect of osteoporosis treatment on mortality: a meta-analysis.
Topics: Age Factors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Denosumab; Diphosphonates; Etidronic Acid; Fractures, Bone; Humans; Imidazoles; Organometallic Compounds; Osteoporosis; Randomized Controlled Trials as Topic; RANK Ligand; Risedronic Acid; Thiophenes; Treatment Outcome; Zoledronic Acid | 2010 |
Osteonecrosis of the jaw and the role of macrophages.
Topics: Alendronate; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone Density Conservation Agents; Denosumab; Diphosphonates; Etidronic Acid; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ibandronic Acid; Imidazoles; Indoles; Jaw Diseases; Macrophages; Magnetic Resonance Imaging; Mevalonic Acid; Monocytes; Mouth Mucosa; Osteoclasts; Osteomyelitis; Osteonecrosis; Positron-Emission Tomography; Pyrroles; Radiography, Panoramic; RANK Ligand; Risedronic Acid; Risk Factors; Signal Transduction; Sunitinib; Tomography, X-Ray Computed; Vitamin D; Zoledronic Acid | 2011 |
Bisphosphonates in multiple myeloma: a network meta-analysis.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Diseases; Clodronic Acid; Diphosphonates; Etidronic Acid; Fractures, Bone; Humans; Imidazoles; Multiple Myeloma; Pamidronate; Randomized Controlled Trials as Topic; Zoledronic Acid | 2012 |
[Bisphosphonate related osteonecrosis of the jaw and infection with Actinomyces].
Topics: Actinomyces; Actinomycosis; Aged; Aged, 80 and over; Alendronate; Anti-Bacterial Agents; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Diseases, Metabolic; Combined Modality Therapy; Diphosphonates; Disease Susceptibility; Etidronic Acid; Female; Humans; Imidazoles; Male; Mandibular Diseases; Maxillary Diseases; Middle Aged; Models, Biological; Neoplasms; Osteitis; Osteoporosis; Retrospective Studies; Risedronic Acid; Zoledronic Acid | 2012 |
Timing of the initiation of bisphosphonates after surgery for fracture healing: a systematic review and meta-analysis of randomized controlled trials.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Bone Remodeling; Diphosphonates; Etidronic Acid; Female; Fracture Healing; Humans; Imidazoles; Male; Middle Aged; Randomized Controlled Trials as Topic; Risedronic Acid; Treatment Outcome; Zoledronic Acid | 2015 |
Bisphosphonates in multiple myeloma: an updated network meta-analysis.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Diseases; Clodronic Acid; Diphosphonates; Disease-Free Survival; Etidronic Acid; Fractures, Bone; Humans; Imidazoles; Multiple Myeloma; Pamidronate; Randomized Controlled Trials as Topic; Spinal Fractures; Zoledronic Acid | 2017 |
Bisphosphosphonate-calcium phosphate cement composite and its properties.
Topics: Alendronate; Animals; Biocompatible Materials; Bone Density Conservation Agents; Calcium Phosphates; Diphosphonates; Drug Carriers; Drug Delivery Systems; Etidronic Acid; Humans; Pamidronate; Zoledronic Acid | 2019 |
Bisphosphonates for Secondary Prevention of Osteoporotic Fractures: A Bayesian Network Meta-Analysis of Randomized Controlled Trials.
Topics: Aged; Alendronate; Bayes Theorem; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Humans; Male; Middle Aged; Network Meta-Analysis; Osteoporotic Fractures; Randomized Controlled Trials as Topic; Risedronic Acid; Secondary Prevention; Zoledronic Acid | 2019 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Clodronic Acid; Denosumab; Diphosphonates; Etidronic Acid; Humans; Male; Network Meta-Analysis; Pamidronate; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Randomized Controlled Trials as Topic; RANK Ligand; Risedronic Acid; Zoledronic Acid | 2020 |
Antiresorptive treatments for corticosteroid-induced osteoporosis: a Bayesian network meta-analysis.
Topics: Adrenal Cortex Hormones; Alendronate; Bayes Theorem; Bone Density Conservation Agents; Denosumab; Etidronic Acid; Glucocorticoids; Humans; Network Meta-Analysis; Osteoporosis; Risedronic Acid; Zoledronic Acid | 2022 |
7 trial(s) available for zoledronic acid and etidronate
| Article | Year |
|---|---|
Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease.
Topics: Administration, Oral; Aged; Alkaline Phosphatase; Biomarkers; Bone and Bones; Bone Remodeling; Diphosphonates; Double-Blind Method; Etidronic Acid; Female; Humans; Imidazoles; Infusions, Intravenous; Male; Osteitis Deformans; Quality of Life; Risedronic Acid; Zoledronic Acid | 2005 |
Is a single infusion of zoledronic acid more effective than oral risedronate for the treatment of patients with Paget's disease?
Topics: Administration, Oral; Adult; Bone Density Conservation Agents; Diphosphonates; Dose-Response Relationship, Drug; Double-Blind Method; Etidronic Acid; Follow-Up Studies; Humans; Imidazoles; Infusions, Intravenous; Osteitis Deformans; Risedronic Acid; Treatment Outcome; Zoledronic Acid | 2006 |
Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alkaline Phosphatase; Bone and Bones; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Follow-Up Studies; Humans; Imidazoles; Infusions, Intravenous; Osteitis Deformans; Risedronic Acid; Zoledronic Acid | 2007 |
Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Analysis of Variance; Bone Density; Bone Density Conservation Agents; Diphosphonates; Double-Blind Method; Drug Administration Schedule; Etidronic Acid; Female; Glucocorticoids; Humans; Imidazoles; Infusions, Intravenous; Least-Squares Analysis; Male; Middle Aged; Osteoporosis; Risedronic Acid; Treatment Outcome; Young Adult; Zoledronic Acid | 2009 |
Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis.
Topics: Administration, Oral; Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Diphosphonates; Double-Blind Method; Drug Administration Schedule; Etidronic Acid; Female; Glucocorticoids; Humans; Imidazoles; Infusions, Intravenous; Lumbar Vertebrae; Male; Menopause; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Prednisone; Risedronic Acid; Sex Factors; Vitamin D; Young Adult; Zoledronic Acid | 2012 |
Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with risedronate.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Diphosphonates; Double-Blind Method; Etidronic Acid; Femur Neck; Glucocorticoids; Hip Joint; Humans; Imidazoles; Lumbar Vertebrae; Male; Middle Aged; Osteoporosis; Risedronic Acid; Young Adult; Zoledronic Acid | 2012 |
Effect on bone turnover markers of once-yearly intravenous infusion of zoledronic acid versus daily oral risedronate in patients treated with glucocorticoids.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Drug Therapy, Combination; Etidronic Acid; Female; Glucocorticoids; Humans; Imidazoles; Infusions, Intravenous; Male; Middle Aged; Osteoporosis; Prednisone; Risedronic Acid; Treatment Outcome; Zoledronic Acid | 2013 |
46 other study(ies) available for zoledronic acid and etidronate
| Article | Year |
|---|---|
An investigation of bone resorption and Dictyostelium discoideum growth inhibition by bisphosphonate drugs.
Topics: Alkyl and Aryl Transferases; Animals; Bone Resorption; Crystallography, X-Ray; Dictyostelium; Diphosphonates; Enzyme Inhibitors; Geranyltranstransferase; Humans; Inhibitory Concentration 50; Models, Molecular; Quantitative Structure-Activity Relationship; Rats | 2002 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Entamoeba histolytica: computer-assisted modeling of phosphofructokinase for the prediction of broad-spectrum antiparasitic agents.
Topics: Amino Acid Sequence; Animals; Antiprotozoal Agents; Binding Sites; Computer Simulation; Diphosphates; Diphosphonates; Drug Design; Drug Evaluation, Preclinical; Entamoeba histolytica; Etidronic Acid; Imidazoles; Models, Molecular; Molecular Sequence Data; Phosphofructokinase-1; Sequence Alignment; Sequence Homology, Amino Acid; Zoledronic Acid | 1997 |
Bisphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts.
Topics: Alkaline Phosphatase; Anti-Inflammatory Agents; Antineoplastic Agents; Bone Development; Calcification, Physiologic; Cell Differentiation; Cell Division; Cells, Cultured; Chelating Agents; Collagen; Diphosphonates; Edetic Acid; Etidronic Acid; Fetus; Gene Expression; Humans; Imidazoles; Osteoblasts; Pamidronate; Proteins; Zoledronic Acid | 2000 |
Distinct mechanisms of bisphosphonate action between osteoblasts and breast cancer cells: identity of a potent new bisphosphonate analogue.
Topics: Bone and Bones; Breast Neoplasms; Cell Differentiation; Diphosphonates; Dose-Response Relationship, Drug; Etidronic Acid; Female; Humans; Imidazoles; Lovastatin; Mevalonic Acid; Osteoblasts; Pregnancy; Structure-Activity Relationship; Tumor Cells, Cultured; Zoledronic Acid | 2002 |
Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats.
Topics: Angiogenesis Inhibitors; Animals; Bone and Bones; Cell Division; Cells, Cultured; Clodronic Acid; Diphosphonates; Endothelium, Vascular; Epithelial Cells; Etidronic Acid; Humans; Ibandronic Acid; Imidazoles; Male; Neovascularization, Physiologic; Orchiectomy; Osteitis Deformans; Prostate; Rats; Rats, Sprague-Dawley; Risedronic Acid; Testosterone; Tissue Distribution; Zoledronic Acid | 2002 |
Clinical pharmacology of potent new bisphosphonates for postmenopausal osteoporosis.
Topics: Alendronate; Diphosphonates; Etidronic Acid; Female; Humans; Ibandronic Acid; Imidazoles; Osteoporosis, Postmenopausal; Risedronic Acid; Zoledronic Acid | 2005 |
Paget's disease and bisphosphonates.
Topics: Administration, Oral; Alendronate; Cost-Benefit Analysis; Diphosphonates; Drug Administration Schedule; Drug Costs; Etidronic Acid; Humans; Imidazoles; Osteitis Deformans; Risedronic Acid; Zoledronic Acid | 2005 |
Paget's disease and bisphosphonates.
Topics: Administration, Oral; Alkaline Phosphatase; Diphosphonates; Disease Progression; Etidronic Acid; Humans; Imidazoles; Osteitis Deformans; Remission Induction; Risedronic Acid; Zoledronic Acid | 2005 |
[Optimizing therapy in Paget disease].
Topics: Administration, Oral; Bone Density Conservation Agents; Diphosphonates; Drug Therapy, Combination; Etidronic Acid; Follow-Up Studies; Humans; Imidazoles; Infusions, Intravenous; Osteitis Deformans; Randomized Controlled Trials as Topic; Risedronic Acid; Zoledronic Acid | 2005 |
Differential effects of bisphosphonates on breast cancer cell lines.
Topics: Alendronate; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Clodronic Acid; Cyclin D1; Diphosphonates; DNA Fragmentation; Etidronic Acid; Female; Flow Cytometry; Humans; Ibandronic Acid; Imidazoles; Pamidronate; Risedronic Acid; RNA, Messenger; Zoledronic Acid | 2007 |
Bisphosphonates inhibit the growth of mesothelioma cells in vitro and in vivo.
Topics: Animals; Cell Division; Cell Line, Tumor; Diphosphonates; Disease Models, Animal; Etidronic Acid; Imidazoles; Mesothelioma; Mice; Phosphorylation; Risedronic Acid; Zoledronic Acid | 2006 |
The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs.
Topics: Animals; Bone Density Conservation Agents; Crystallography, X-Ray; Diphosphonates; Etidronic Acid; Female; Geranyltranstransferase; Humans; Imidazoles; Models, Molecular; Molecular Sequence Data; Molecular Structure; Nitrogen; Protein Binding; Protein Conformation; Recombinant Proteins; Risedronic Acid; Zoledronic Acid | 2006 |
[Substance properties of zoledronate make it possible: bisphosphonate therapy only once yearly].
Topics: Aged; Aged, 80 and over; Alendronate; Biological Availability; Bone Density Conservation Agents; Diphosphonates; Double-Blind Method; Etidronic Acid; Female; Geranyltranstransferase; Humans; Imidazoles; Male; Multicenter Studies as Topic; Osteitis Deformans; Osteoporosis, Postmenopausal; Patient Compliance; Placebos; Randomized Controlled Trials as Topic; Risedronic Acid; Surveys and Questionnaires; Time Factors; Zoledronic Acid | 2006 |
Yearly zoledronic acid in postmenopausal osteoporosis.
Topics: Administration, Oral; Aged; Alendronate; Atrial Fibrillation; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Fractures, Bone; Humans; Imidazoles; Osteoporosis, Postmenopausal; Risedronic Acid; Zoledronic Acid | 2007 |
NMR investigations of the static and dynamic structures of bisphosphonates on human bone: a molecular model.
Topics: Alendronate; Biochemistry; Bone and Bones; Bone Density Conservation Agents; Crystallography, X-Ray; Diphosphonates; Etidronic Acid; Humans; Hydrogen; Imidazoles; Magnetic Resonance Spectroscopy; Models, Molecular; Molecular Conformation; Pamidronate; Protein Structure, Tertiary; Risedronic Acid; Zoledronic Acid | 2008 |
Farnesyl pyrophosphate synthase enantiospecificity with a chiral risedronate analog, [6,7-dihydro-5H-cyclopenta[c]pyridin-7-yl(hydroxy)methylene]bis(phosphonic acid) (NE-10501): Synthetic, structural, and modeling studies.
Topics: Algorithms; Binding Sites; Bone Density Conservation Agents; Carcinoma; Computer Simulation; Crystallography, X-Ray; Diphosphonates; Enzyme Inhibitors; Etidronic Acid; Farnesyltranstransferase; Humans; Imidazoles; Inhibitory Concentration 50; Magnesium; Models, Chemical; Organophosphonates; Pyridines; Risedronic Acid; Stereoisomerism; Structure-Activity Relationship; Zoledronic Acid | 2008 |
Maximizing effectiveness of bisphosphonate therapy for osteoporosis.
Topics: Administration, Oral; Alendronate; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Fractures, Spontaneous; Humans; Imidazoles; Medication Adherence; Osteoporosis; Physician-Patient Relations; Risedronic Acid; Risk Factors; Zoledronic Acid | 2008 |
[New bisphosphonates and trends in drug therapy for osteoporosis: preface].
Topics: Alendronate; Bone Density Conservation Agents; Clinical Trials as Topic; Diphosphonates; Etidronic Acid; Evidence-Based Medicine; Humans; Imidazoles; Osteoporosis; Risedronic Acid; Zoledronic Acid | 2009 |
Glucocorticoid-induced osteoporosis: hope on the HORIZON.
Topics: Administration, Oral; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Glucocorticoids; Humans; Imidazoles; Infusions, Intravenous; Osteoblasts; Osteoporosis; Research Design; Risedronic Acid; Treatment Outcome; Zoledronic Acid | 2009 |
Corticosteroids: no drug prevention of fractures needed.
Topics: Adrenal Cortex Hormones; Alendronate; Bone and Bones; Bone Density; Bone Density Conservation Agents; Calcium, Dietary; Diphosphonates; Etidronic Acid; Fractures, Bone; Humans; Imidazoles; Osteoporosis; Randomized Controlled Trials as Topic; Risedronic Acid; Risk Factors; Steroids; Teriparatide; Vitamin D; Zoledronic Acid | 2009 |
Bisphosphonates do not inhibit periosteal bone formation in estrogen deficient animals and allow enhanced bone modeling in response to mechanical loading.
Topics: Alendronate; Animals; Bone and Bones; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Imidazoles; Osteogenesis; Osteoporosis; Ovariectomy; Rats; Risedronic Acid; Zoledronic Acid | 2010 |
Management of metastatic bone pain with repeated doses of rhenium 186-HEDP in patients under therapy with zoledronic acid: a safe and additively effective practice.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Etidronic Acid; Female; Humans; Imidazoles; Male; Middle Aged; Neoplasm Metastasis; Organometallic Compounds; Pain; Pain Measurement; Prostatic Neoplasms; Treatment Outcome; Zoledronic Acid | 2009 |
Differences between bisphosphonates in binding affinities for hydroxyapatite.
Topics: Bone Density Conservation Agents; Chromatography, Liquid; Diphosphonates; Durapatite; Etidronic Acid; Imidazoles; Risedronic Acid; Spectrophotometry, Ultraviolet; Zoledronic Acid | 2010 |
Inhibition of necrotic actions of nitrogen-containing bisphosphonates (NBPs) and their elimination from bone by etidronate (a non-NBP): a proposal for possible utilization of etidronate as a substitution drug for NBPs.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Bone Resorption; Diphosphonates; Ear, External; Etidronic Acid; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Imidazoles; Inflammation Mediators; Injections, Intraperitoneal; Injections, Subcutaneous; Interleukin-1; Male; Mice; Mice, Inbred BALB C; Necrosis; Osteonecrosis; Osteosclerosis; Pamidronate; Pravastatin; Radionuclide Imaging; Radiopharmaceuticals; Risedronic Acid; Technetium; Tibia; Time Factors; Zoledronic Acid | 2010 |
An in vitro assay to measure targeted drug delivery to bone mineral.
Topics: Alendronate; Anabolic Agents; Bone and Bones; Bone Density Conservation Agents; Diphosphonates; Drug Delivery Systems; Durapatite; Etidronic Acid; Humans; Ibandronic Acid; Imidazoles; Nuclear Magnetic Resonance, Biomolecular; Pamidronate; Risedronic Acid; Zoledronic Acid | 2010 |
Intravenous zoledronic acid: what are the indications for male osteoporosis?
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Clinical Trials as Topic; Diphosphonates; Etidronic Acid; Humans; Imidazoles; Male; Osteoporosis; Parathyroid Hormone; Risedronic Acid; Risk Factors; Testosterone; Zoledronic Acid | 2010 |
Nitrogen-containing bisphosphonates can inhibit angiogenesis in vivo without the involvement of farnesyl pyrophosphate synthase.
Topics: Animals; Cell Proliferation; Cell Survival; Cells, Cultured; Chick Embryo; Chorioallantoic Membrane; Diphosphonates; Endothelial Cells; Etidronic Acid; Geranyltranstransferase; Humans; Imidazoles; Male; Neovascularization, Pathologic; Rats; Rats, Sprague-Dawley; Risedronic Acid; Zoledronic Acid | 2011 |
The effects of topical application of bisphosphonates on replanted rat molars.
Topics: Administration, Topical; Alendronate; Animals; Bone Density Conservation Agents; Citric Acid; Dental Cementum; Dentin; Desiccation; Diphosphonates; Etidronic Acid; Imidazoles; Male; Molar; Rats; Rats, Sprague-Dawley; Root Canal Therapy; Root Resorption; Temperature; Time Factors; Tooth Replantation; Tooth Root; Tooth Socket; Zoledronic Acid | 2010 |
Outcome of patients with early breast cancer receiving nitrogen-containing bisphosphonates: a comparative analysis from the Metropolitan Detroit Cancer Surveillance System.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Etidronic Acid; Female; Humans; Ibandronic Acid; Imidazoles; Michigan; Middle Aged; Neoplasm Staging; Population Surveillance; Registries; Retrospective Studies; Risedronic Acid; Survival Analysis; Treatment Outcome; Zoledronic Acid | 2010 |
Bisphosphonate-related osteonecrosis of jaws in 3 osteoporotic patients with history of oral bisphosphonate use treated with single yearly zoledronic acid infusion.
Topics: Aged; Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Diseases, Metabolic; Diphosphonates; Etidronic Acid; Female; Follow-Up Studies; Humans; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Mandibular Diseases; Maxillary Diseases; Middle Aged; Osteoporosis, Postmenopausal; Risedronic Acid; Tooth Extraction; Tooth Socket; Zoledronic Acid | 2012 |
Lipophilic analogs of zoledronate and risedronate inhibit Plasmodium geranylgeranyl diphosphate synthase (GGPPS) and exhibit potent antimalarial activity.
Topics: Animals; Antimalarials; Calorimetry; Crystallography, X-Ray; Diphosphonates; Enzyme Inhibitors; Erythrocytes; Etidronic Acid; Farnesyltranstransferase; High-Throughput Screening Assays; Humans; Imidazoles; Lipids; Mice; Models, Molecular; Parasitemia; Plasmodium; Plasmodium falciparum; Plasmodium vivax; Protein Binding; Risedronic Acid; Survival Analysis; Terpenes; Zoledronic Acid | 2012 |
Paget disease of bone - an update.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Humans; Imidazoles; Middle Aged; Osteitis Deformans; Risedronic Acid; Zoledronic Acid | 2012 |
Third-generation bisphosphonates for treatment of sensorineural hearing loss in otosclerosis.
Topics: Adult; Aged; Audiometry, Pure-Tone; Auditory Threshold; Bone Conduction; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Hearing Loss, Sensorineural; Humans; Imidazoles; Male; Middle Aged; Otosclerosis; Retrospective Studies; Risedronic Acid; Speech Perception; Tomography, X-Ray Computed; Treatment Outcome; Zoledronic Acid | 2012 |
In vitro cytotoxicity of zoledronate (nitrogen-containing bisphosphonate: NBP) and/or etidronate (non-NBP) in tumour cells and periodontal cells.
Topics: Adenocarcinoma; Annexin A5; Apoptosis; Bone Density Conservation Agents; Carcinoma, Squamous Cell; Cell Culture Techniques; Cell Line, Tumor; Cell Survival; Cells, Cultured; Coloring Agents; Dental Cementum; Diphosphonates; Endothelial Cells; Endothelium, Vascular; Etidronic Acid; Fibroblasts; Fluorescein-5-isothiocyanate; Fluorescent Dyes; Gingiva; Humans; Imidazoles; Leukemia, Monocytic, Acute; Mesenchymal Stem Cells; Periodontal Ligament; Propidium; Tetrazolium Salts; Umbilical Veins; Zoledronic Acid | 2013 |
Bisphosphonate-related osteonecrosis of jaw (BRONJ) in Japanese population: a case series of 13 patients at our clinic.
Topics: Administration, Oral; Adrenal Cortex Hormones; Aged; Aged, 80 and over; Alendronate; Anti-Bacterial Agents; Arthritis, Rheumatoid; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diabetes Complications; Diphosphonates; Etidronic Acid; Female; Follow-Up Studies; Humans; Imidazoles; Infusions, Parenteral; Japan; Male; Middle Aged; Oral Surgical Procedures; Osteoporosis; Prostatic Neoplasms; Risedronic Acid; Treatment Outcome; Wound Healing; Zoledronic Acid | 2013 |
Substantial under-treatment among women diagnosed with osteoporosis in a US managed-care population: a retrospective analysis.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Calcitonin; Cohort Studies; Diphosphonates; Etidronic Acid; Female; Humans; Ibandronic Acid; Imidazoles; Managed Care Programs; Middle Aged; Osteoporosis; Raloxifene Hydrochloride; Retrospective Studies; Risedronic Acid; Teriparatide; United States; Zoledronic Acid | 2014 |
Inhibition of phosphate transporters ameliorates the inflammatory and necrotic side effects of the nitrogen-containing bisphosphonate zoledronate in mice.
Topics: Animals; Bone Resorption; Clodronic Acid; Diphosphonates; Etidronic Acid; Female; Foscarnet; Imidazoles; Mice; Mice, Inbred BALB C; Molecular Structure; Necrosis; Osteitis; Phosphate Transport Proteins; Zoledronic Acid | 2013 |
The cell cycle arrest and the anti-invasive effects of nitrogen-containing bisphosphonates are not mediated by DBF4 in breast cancer cells.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Cycle Checkpoints; Cell Cycle Proteins; Cell Line, Tumor; Cell Movement; Cell Proliferation; Diphosphonates; Drug Screening Assays, Antitumor; Etidronic Acid; Female; Humans; Imidazoles; Inhibitory Concentration 50; Neoplasm Invasiveness; Pamidronate; Risedronic Acid; Zoledronic Acid | 2014 |
A simple evaluation method for early detection of bisphosphonate-related osteonecrosis of the mandible using computed tomography.
Topics: Administration, Intravenous; Administration, Oral; Alendronate; Alveolar Process; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density; Bone Density Conservation Agents; Case-Control Studies; Diphosphonates; Early Diagnosis; Etidronic Acid; Female; Humans; Image Processing, Computer-Assisted; Imidazoles; Male; Mandible; Mandibular Diseases; Middle Aged; Osteolysis; Osteosclerosis; Pamidronate; Risedronic Acid; Risk Factors; Time Factors; Tomography, X-Ray Computed; Zoledronic Acid | 2014 |
Efficacy, effectiveness and side effects of medications used to prevent fractures.
Topics: Alendronate; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Calcium Compounds; Denosumab; Diphosphonates; Etidronic Acid; Evidence-Based Medicine; Hip Fractures; Humans; Ibandronic Acid; Imidazoles; Osteoporosis; Osteoporotic Fractures; Raloxifene Hydrochloride; Risedronic Acid; Risk Assessment; Spinal Fractures; Teriparatide; Thiophenes; Treatment Outcome; Vitamin D; Zoledronic Acid | 2015 |
Probenecid as a sensitizer of bisphosphonate-mediated effects in breast cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Bone Neoplasms; Breast Neoplasms; Caspase 3; Caspase 7; Cell Line, Tumor; Cell Survival; Connexins; Diphosphonates; Etidronic Acid; Female; Hemiterpenes; Humans; Ibandronic Acid; Imidazoles; MCF-7 Cells; Multidrug Resistance-Associated Proteins; Nerve Tissue Proteins; Organophosphorus Compounds; Osteoclasts; Phosphate Transport Proteins; Probenecid; Risedronic Acid; Zoledronic Acid | 2014 |
Cranial base pathology in pediatric osteogenesis imperfecta patients treated with bisphosphonates.
Topics: Adolescent; Bone Density Conservation Agents; Child; Child, Preschool; Diphosphonates; Drug Administration Schedule; Etidronic Acid; Female; Follow-Up Studies; Humans; Imidazoles; Infant; Kaplan-Meier Estimate; Logistic Models; Male; Osteogenesis Imperfecta; Pamidronate; Platybasia; Retrospective Studies; Risedronic Acid; Skull Base; Zoledronic Acid | 2015 |
Differential modulation of zoledronate and etidronate in osseous healing of an extracted socket and tibia defect.
Topics: Animals; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density; Bone Density Conservation Agents; Bone Regeneration; Diphosphonates; Etidronic Acid; Female; Imidazoles; Random Allocation; Rats; Rats, Sprague-Dawley; Tibia; Tooth Extraction; Tooth Socket; Wound Healing; X-Ray Microtomography; Zoledronic Acid | 2017 |
Delineating residues for haemolytic activities of snake venom cardiotoxin 1 from Naja naja as probed by molecular dynamics simulations and in vitro validations.
Topics: Amino Acid Sequence; Animals; Antidotes; Cholesterol; Cobra Cardiotoxin Proteins; Diphosphonates; Disulfides; Elapid Venoms; Elapidae; Erythrocyte Membrane; Etidronic Acid; Hemolysis; High-Throughput Screening Assays; Humans; Imidazoles; Molecular Dynamics Simulation; Phosphatidylcholines; Phosphatidylethanolamines; Phosphatidylserines; Protein Domains; Protein Structure, Secondary; Small Molecule Libraries; Structure-Activity Relationship; User-Computer Interface; Zoledronic Acid | 2017 |
Exploring methods for comparing the real-world effectiveness of treatments for osteoporosis: adjusted direct comparisons versus using patients as their own control.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Case-Control Studies; Diphosphonates; Etidronic Acid; Female; Fractures, Bone; Humans; Imidazoles; Incidence; Middle Aged; Netherlands; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Registries; Risedronic Acid; Risk Factors; Sweden; Treatment Outcome; Zoledronic Acid | 2017 |